



Abstract— This study aims to evaluate the efficacy of two 
different drugs in their effects on memory and discrimination 
learning in a dual, controlled mouse model of amnesia, and to 
relate the findings to their pharmacokinetic and 
pharmacodynamics profiles. It also aims at validating a sub-acute 
scopolamine dose protocol as a model of rodent amnesia, 
specifically of emotional memory. 
The Exteroceptive models used include a Y-maze and an 
Elevated plus Maze (EPM). The Interoceptive models used are 
two different dose protocols of an amnesic drug, Scopolamine in 
forty-eight Swiss Albino mice, categorized into an acute and a 
sub-acute induction division, each of which later received fixed 
human equivalent doses of two drugs, apart from saline and 
scopolamine. Each animal was then evaluated for their Novelty 
Object Recognition (NOR) memory, and visuo-spatial memory, 
on the Y-maze and the EPM, respectively. The results of the 
Novelty Preference Test (NPT) and EPM test were analysed using 
Analysis of Variance. 
The efficacy of Rimonabant in improving NOR memory was 
statistically higher than in saline and model control groups, more 
so in the acute induction. Its efficacy in enhancing visuo-spatial 
memory was less, although comparable to that on NOR memory.  
The efficacy of Valsartan was lower than the NOR Recognition 
Indices of other groups, although insignificant statistically. Sub-
acute induction resulted in increased amnesia and anxiety in the 
Valsartan group on both mazes, the former being comparable to 
that noted in scopolamine group. 
Rimonabant is a memory enhancer, in terms of both 
recognition and spatial memory. Valsartan is a pro-amnesic drug 
in a sub-acute induction, in which it lead to increased anxiety 
additionally. Hence, sub acute scopolamine protocol could be a 
novel model of emotional memory. Though many drawbacks were 
noted in the study, the drug effects could be explained by 
pharmacokinetic data and pharmacodynamic effects. This pilot 
study could be used for correlating the results in human 
conditions involving memory. 
 
 Index Terms— Cannabinoid Receptor, Angiotensin Receptor, 
Rimonabant, Valsartan, acute Scopolamine amnesia, maze 
learning, novelty object recognition memory, spatial memory, sub-
acute scopolamine amnesia, y-maze, elevated plus maze 
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I. INTRODUCTION 
ngiotensin is a group of peptides consisting mainly of 
Angiotensin I, Angiotensin II, Angiotensin III, and 
Angiotensin IV. Each of these molecules can activate specific 
receptors for Angiotensin, named AT 1-4. Although each of 
these receptors has specific agonists and antagonists, they 
could, in theory, be occupied by any of the above peptide 
ligands.   
Almost all the components of the Angiotensin system are 
found in the central nervous system. They regulate many 
physiological and pathophysiological processes and are 
responsible for maintaining vital functions, ranging from blood 
pressure regulation to sexual function. Perhaps the most 
important of these functions relevant to the current study is 
memory and its regulation and modulation.1 
Similar to this system in its central role, is the 
endocannabinoid system. This system consists of two well 
characterized (CB1, CB2) and one poorly characterized 
receptor (Anandamide Receptor).2 The endocannabinoids are a 
group of lipid-derived compounds including Anandamide 
(AEA), Virodamine, Noladin Ether, ∆ 9-
Tetrahydrocannabinol, and 2-Arachidonyl derivatives.  
Cannabinoids mediate dopamine induced increase in reward 
behaviour through activation of CB1 receptors in nucleus 
accumbens.3 Rimonabant could act through this pathway in the 
brain to increase acquisition of reward memory induced by 
psychostimulants like cocaine. Moreover, disrupting CB1 
signalling by knocking out CB1 gene and then treating the 
mice with Rimonabant repeatedly impairs spatial memory 
extinction on Morris water maze.4 There is also evidence that 
endocannabinoids affect inhibitory avoidance learning, but 
their effects on working long term memory lack proper 
evidence.5  
On similar lines of reference, Angiotensin system through 
AT4 receptors and AT1-containing neurons in areas of brain, 
mediate memory and learning.6 Angiotensin IV-mediated 
antagonism of hippocampal neurotransmission using an AT4-
specific antagonist attenuates acetylcholine release.7 It has 
already been an established fact8 that increases in hippocampal 
acetylcholine improves memory and even prevents memory 
decline due to deposition of insoluble beta amyloid in brain.9,10 
Hence, we tried to evaluate whether or not Rimonabant and 
valsartan, acting through distinct mechanisms, improve 
working long term memory and spatial-emotional memory.  
This study aims to evaluate the acute and sub-acute 
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FIGURE 1: Mouse Elevated plus Maze; Note the 
enclosed arms have thicker walls (in white shade) and 
open arms have no walls (shown here as having a thin 
layer of single wall) 
efficacies of Rimonabant and Valsartan in improving cognition 
in scopolamine mouse model of amnesia. 
The hypothesis was that administering each drug to different 
groups of animals treated with memory disruptor 
anticholinergic, scopolamine, could lead to memory changes 
related, in some way, to the cholinergic system. 
II. MATERIALS & METHODS 
A. Ethical & Regulatory Considerations: 
 The study was accepted and permitted ethically by the 
Institutional Animal Ethics Committee (IAEC Approval 
Number: SRU/CEFT/LE/016/111/2009, dated 06 August 
2009), and was conducted in a laboratory-cum-animal facility 
(SRU-CEFT) following Committee for the Purpose of Control 
& Supervision of Experiments on Animals (CPCSEA) and 
Good Laboratory Practices (GLP) guidelines. 
 
B. Materials: 
Scopolamine was purchased from Sigma-Aldrich, India, and 
the study drugs Valsartan and Rimonabant were purchased 
from local manufacturers. Mazes used for this study were of 
the standard dimensions: 
 
EPM    :  18 cm × 5 cm × 37 cm 
Y-maze:  75 cm × 16 cm × 35 cm,  
* Dimensions of each maze = length (total) × breadth (total) 
× height (total). The following figures (Figs. 1 & 2) depict the 















The study drugs: Rimonabant is a Cannabinoid receptor 
partial antagonist that was initially approved for treatment of 
obesity as an anorectic drug and later retracted due to high 
incidence of suicidal tendencies. Valsartan is an Angiotensin 
receptor antagonist that is also used clinically as 
antihypertensive drug. Both were given separately to two 
different groups by oral gavage. Rimonabant was given as a 
3% solution in water, whilst valsartan as a 10% aqueous 
solution. 
Controls: Saline 0.5% was used to serve as non-vehicle 
non-treatment control for the first group. Scopolamine 3% in 
water served as the memory decline control for the acute 
study, whereas scopolamine 0.5% in water served as the 
amnesia control for the sub-chronic study. The study design 
and duration did not warrant the need for ageing control to 
remove ageing-related amnesia as a confounder. 
Saline and scopolamine were both given by intra-peritoneal 
route. Scopolamine was injected also in the two test groups, 
prior to drug treatments.  
Animals & grouping: Forty eight Swiss albino mice were 
obtained and grouped into two divisions – acute and sub-acute 
amnesia induction divisions. Under each division, four equally 
numbered groups were obtained randomly as per body weight 
using a table of random numbers.  
Exteroceptive models: A study plan using a y-maze 
protocol was used to evaluate the working and novelty 
preference long term memory. On similar lines of reference, an 
elevated plus maze protocol was used to evaluate the spatial 
long term memory. Both forms of memory were not evaluated 
using the test drugs before. Both mazes were also used to study 
other possible effects like those on anxiety, behaviour, and 
motor activities. 
Interoceptive models: Scopolamine was used to induce 
amnesia as a single high dose (acute amnesia) and as multiple 
daily once low doses for seven days (sub-acute amnesia). As it 
disrupts muscarinic system-mediated cholinergic transmission, 
it was the best Interoceptive model for the present study. 
FIGURE 2: Y-maze: Note the two arms, novel and start 
arms are of equal lengths; the third longer arm is the 
familiar arm (not shown: the guillotine door in the 
central platform, adjacent novel arm opening). 
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The following diagram depicts the animal grouping, 







Each division was assessed for the parameters using 
separate animals. 
 
Y-Maze: The novelty preference test (NPT) was used to 
assess the working long term memory and novelty memory on 
y-maze after acute and sub-acute scopolamine treatment. In 
this test, the asymmetrical y-maze was used (refer figure 2), in 
which two arms were of equal dimensions, the third being 
longer in length. One of the equal arms had a guillotine door 
near its junction with the central platform, where all three arms 
meet.  
This door was designed in a manner so as to allow opening 
or closing of this arm, as and when required. This arm 
equipped with the door was the novel (N) arm; the other 
equivalent adjacent arm was the start (S) arm; the longer arm 
was the familiar (F) arm. The familiar arm was longer so as to 
neutralize the confounding effects of initial exploratory trials 
in its longer length, relative to the novel arm which was closed 
in these trials. 
The recognition index (R.I.) was used in later acquisition 
trials (one hour, two hour, four hour, and twenty four hours, 
post last drug treatment). It is a measure of novelty preference 
working long term memory, based in the hippocampal 




R.I. = Recognition Index, 
NAE = Number of Arm Entries, 
N & F = Novel & Familiar arms. 
 
EPM: The transfer latency (T.L.) test was used to assess the 
spatial memory that was fear-related. The maze consisted of 
four arms of equal dimensions at ninety degrees orientation to 
each other in the horizontal plane, elevated from the floor. The 
two opposite pairs of arms differed from each other, in that 
one pair was open (no walls), the other one enclosed 
(surrounded by walls on all three sides, except that facing the 
central platform).  In this test, in a single trial each in the two 
divisions, the mouse was placed in the central platform, that it 
faced one of the open arms. The upper cut-off time was 90  
Seconds, above which if the mouse did not move into either 
of the enclosed arms, three fourths of its body length inside the 
arm, it was discarded from the study. The endpoint was 
transfer latency, the time taken by it to move from its starting 
initial position in the maze to this enclosed arm, is a direct 
measure of its Nootropic effect, inversely its anxiogenic effect.  
Scopolamine Treatments: Scopolamine is an anticholinergic 
drug used as a transdermal therapeutic system in patients with 
motion sickness. It is also an amnestic agent, when injected in 
rodents.  
In the acute amnesia induction, it is injected by 
intraperitoneal route as a single high dose of 3 mg/kg in 
mouse. This was followed by single oral drug treatments. 
For the sub acute induction, it can be injected in multiple 
low doses on a daily basis for 7, 14, 21 days. In the present 
study, it was used as a daily 0.3-0.5 mg/kg injection for seven 
days, followed by drug treatments for an another three days.  
 
D. Statistical Analyses: 
Single factor analysis of variance (ANOVA) was used to 
compare all the parameters in each group, followed by 
appropriate post-hoc tests like Tukey test or Bonferroni-Holm 
test. Statistical significance was kept at less than five percent.  
 
All tests were performed using MS-excel 2010 and Daniel 




A. Baseline characteristics: 
The body weight of all the animals used fell in the 23-36 g 
range at the baseline. They were then randomized based on 
these weights into two divisions, presumably weighed equally 
group-wise. The numbers of male and female mice in each 
division were comparable. 
FIGURE 3: Study Grouping and Treatment-Evaluation 
Plan 
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B. Y-maze: latency to locomotion: 
Post analysis of variance of the data depicted in figure 5, 
one can deduce that the comparison of sub-acute induction 
valsartan group was significantly different from the latencies in 
all other groups, although equal variances could not be 
assumed (p < 0.05). From figure 5, one can infer the above 
result since, it is that only group latency that is deviating from 
the normal value (since rodents are exploratory, latency will 








C. Acute division: elevated plus maze: 
The acute scopolamine induction in mice and the 
subsequent testing of spatial memory on the elevated plus 
maze showed statistically significant intergroup comparison 
differences in the transfer latencies between all two-group 
comparisons except that between Rimonabant group and saline 
control group ( p = 0.14).  
This would mean that the Rimonabant group did not differ 
significantly in its Nootropic efficacy as the saline control 
group. Additionally the Valsartan group was comparable to the 
scopolamine group in its pro-amnestic efficacy in a statistically 
significant manner (p = 0.001). The following figure (Fig. 6) 









D. Sub-acute division: elevated plus maze: 
In this test, one can appreciate from figure 7, that valsartan 
group is comparable to scopolamine group in its spatial 
memory disruption, compared to the other two groups. Note 
that 100% impairment refers to the condition when transfer 











FIGURE 5: Shows semi-logarithmic plots of latencies 
to locomotion (seconds) of all groups in each division 
(centripetal axis) against individual mouse ID 
(circumferential axis) 
FIGURE 4: Baseline Body Weight Characteristics 
FIGURE 6: Depicts line plot of transfer latencies 
(seconds) of all four groups in acute amnesia division. 
FIGURE 7: Group-Wise Spatial Memory 
Performance on EPM with the Trial Cut-Off as 
100%; Sub-Acute Avg. T.L. 
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E. Y-maze: recognition indices: 
Though the basic assumptions for ANOVA were met with 
reference to the y maze NPT, and further, an insignificant 
comparison (p>0.05), the results are important in explaining 
the temporal actions of the treatments on memory (Refer 










A. Y-maze Results: 
As notable form figure 9, the memory improvement was 
stable among the four groups in the acute amnesia model more 
than in the 24 hour trial. There tends to be better intergroup 
comparison in sub acute than in acute division, and a better 
improvement in working memory in 24 hour trial than in acute 
amnesia trials. Even in the sub acute division, performance 
was better in scopolamine and valsartan groups, as a paradox. 
Finally, Rimonabant group was borderline (0.6%) in its 
memory effects in sub acute division. The paradoxical effects 
could be partially explained by U-shaped dose response 
relationship that is inherent of most of the toxicological 
compounds like scopolamine.11,12,13,14 Valsartan could follow 
similar effect relationship the peaks might be mediated by AT1 
and later by AT4 receptors, the trough by AT2 receptors, 
owing probably to differential affinities of valsartan to these 
receptors. 
Rimonabant did show borderline memory improvement 
which may be due to its multiple dosing which did not have the 
efficacy in modulating dopaminergic system transmission 
through CB1 receptors, and due to its unfavorable 









B. EPM Results: 
From figures 6 & 7, one can conclude the similarly 
efficacious detrimental effects of both valsartan and 
scopolamine groups on spatial fear-related memory acutely 
and sub acutely. There was some improvement with 
Rimonabant treatment with spatial memory acutely. Of notable 
is that the valsartan showed increased anxiety on open arms on 
the EPM, as shown by transfer latencies approaching the cut-
off times in the sub-acute amnesia model, and increased 
rearing on the open arms. 
 
C. Extrapolation of the results to human beings: 
The results could be extrapolated readily to human disorders 
like vascular and degenerative dementias. Rimonabant is 
moderately nootropic in acute dementia where spatial memory 
is disrupted, like delirium and Korsakoff Wernicke’s psychosis 
and acute epileptic syndromes involving temporal lobes. 
Valsartan may be effective more in vascular than degenerative 
dementias like lewy-body and Alzheimer’s’ type; it may even 
cause working memory disruption in the latter types of 
dementias. 
 
D. Pharmacodynamic & pharmacokinetic considerations: 
Evidence also indicates the presence of interactive synaptic 
pathways and neural networks underlying the intertwined 
communicative neuroeffectors that could partly explain the 
drugs’ effects observed in this study. 15 Indeed such 
interactions are now known to mediate key physiological 
processes, including those of cannabinoid, and, gastrointestinal 
with neurokininergic, 16 and cognitive and addictive behavior 
with glutaminergic and GABAergic pathways. 17 In contrast to 
Cannabinoid system, direct stimulation of cognitive processes 
by Angiotensin II 18 and Angiotensin IV 19, 20 ligands have been 
known, in-spite of controversial 21, 22, 23, 24 26 mechanisms. 
Interfacing such results with the accepted mechanisms of 
FIGURE 8: Group-Wise Temporal Y-Maze Novelty 
Recognition Indexes Pattern 
Figure 9: GroupWise Trend Lines for Y-Maze NPT 
Performances in Acute & Sub acute Amnesia (Error 
Bars Denote Avg. R.I. ± S.E.M.) 
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memory processes evaluated in this study, and, using the 
results of this study, a working model could be developed for 
the memory actions of both study drugs, as follows (figure 10 















As the figure above (Fig. 10) clearly indicates, the three 
neuroeffector systems, viz. Muscarinic (represents 
Scopolamine model), Cannabinoid (represents Rimonabant’s 
action), and Peptidergic (Angiotensin system represents 
Valsartan’s mode of action) systems are intertwined in brain 
areas to display possibly the phenotypic results observed in 
this study.  
 
The pharmacokinetic surrogate endpoints involved have not 
been summarized previously elsewhere as a timeline. 
Scopolamine follows “hormesis” dose-response curves (U-
shaped in contrast to bell shaped) owing to its toxic 
mechanism on cholinergic system14 in causing amnesia over its 
four-five half-live period. Note the dual-shaped nootropic-
amnesic action of Valsartan, and bimodal action of 
Rimonabant as a nootropic agent, over each of their four-five 











The above figure (Fig. 11) states no more than that 
pharmacokinetic parameters must be carefully prioritized a-
priori in planning such multi-drug-efficacy evaluations.  
 
E. Drawbacks: 
Although the study lacks statistical power and a 
considerable effect size, it must be considered as a pilot study, 
and encourage the evaluation of these drugs on memory both 
preclinically and clinically, since, Rimonabant could even 
reverse memory loss as a novel drug, whilst valsartan could be 
disrupting memory in hypertensive patients on this medication. 
Infact Rimonabant is known for its pleotropic effects in human 
beings.25 
Biochemical parameters could not be evaluated herein due 
to financial constraints on the author. 
 
F. Conclusion: 
Both cannabinoid and angiotensin systems could play 
critical roles in cognition and behaviour, that could commonly 
be related to cholinergic system. The study must be definitely 
followed up by further evaluations, aiming to explain the 
paradoxes in this study. 
Other forms of memory and cognitive processes must also 
be considered in the use of both the study drugs for further 
research and in clinical practice. Indeed this area of cognitive 
psychology remains unexplored, though it may be yet another 
impossible illusion much like the Penrose triangle. 
FIGURE 10: A WORKING MODEL TO EXPLAIN 
THE PHARMACODYMAMIC EFFECTS OF THE 
TWO DRUGS USED IN THIS STUDY (NOR = 
Novelty object recognition memory), M1, N-N, AT1-
4 = Neurotransmitter receptors, DA, GABA, NMDA, 
5-HT, Ach = Neurotransmitters, CRH = Hormonal 
transmitter 
FIGURE 11: TIME-LINE OF ACTION OF THE 
STUDY DRUGS AND AMNESIC INDUCER ON 
BOTH FORMS OF MEMORY TAKEN 
TOGETHER (Figure not to scale) 
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